Session Information

Free Paper

[FP-FR-17] AMD Therapy
Go back
print
Day
Apr 04 (Fri)
Time
08:30 - 10:00
Room
Room 1 - Tokyo International Forum Hall A
Topic
Retina - Medical
Chair/Coordinator
Chair)Gisbert Richard、Chair)Ursula Schmidt-Erfurth

Duration 5min, Q&A 3min

FP-FR-17-1 / 

Retina - Medical

Baseline Characteristics of the First 10,000 Patients with Wet AMD, DME, or RVO Treated with Ranibizumab 0.5 mg in Routine Clinical Practice: The LUMINOUS Study

Paul Mitchell

Baseline Characteristics of the First 10,000 Patients with Wet AMD, DME, or RVO Treated with Ranibizumab 0.5 mg in Routine Clinical Practice: The LUMINOUS Study

Duration 5min, Q&A 3min

FP-FR-17-2 / 

Retina - Medical

Three-Year Outcomes Following Intravitreal Ranibizumab for Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy in Japanese Patients

Yuji Oshima

Three-Year Outcomes Following Intravitreal Ranibizumab for Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy in Japanese Patients

Duration 5min, Q&A 3min

FP-FR-17-3 / 

Retina - Medical

Early and Slow >15 Letter Gainers to Ranibizumab Treatment in Neovascular Age-Related Macular Degeneration: A Retrospective Analysis from the ANCHOR, MARINA, HARBOR, and CATT Trials

Richard Gale

Early and Slow >15 Letter Gainers to Ranibizumab Treatment in Neovascular Age-Related Macular Degeneration: A Retrospective Analysis from the ANCHOR, MARINA, HARBOR, and CATT Trials

Duration 5min, Q&A 3min

FP-FR-17-4 / 

Retina - Medical

Treat and Extend Versus Treat and Observe: A Cost-Effectiveness Analysis of Ranibizumab in the Treatment of Wet AMD

Pilar Calvo

Treat and Extend Versus Treat and Observe: A Cost-Effectiveness Analysis of Ranibizumab in the Treatment of Wet AMD

Duration 5min, Q&A 3min

FP-FR-17-5 / 

Retina - Medical

Tachyphylaxis During Ranibizumab Treatment of Exudative Age-Related Macular Degeneration

Sengul Ozdek

Tachyphylaxis During Ranibizumab Treatment of Exudative Age-Related Macular Degeneration

Duration 5min, Q&A 3min

FP-FR-17-6 / 

Retina - Medical

Four-Month Results of Intravitreal Aflibercept for Neovascular Age-Related Maculardegeneration in Eyes Previously Treated with Ranibizumab

Ryo Obata

Four-Month Results of Intravitreal Aflibercept for Neovascular Age-Related Maculardegeneration in Eyes Previously Treated with Ranibizumab

Duration 5min, Q&A 3min

FP-FR-17-7 / 

Retina - Medical

Post Hoc Analysis of Visual Acuity Outcomes in the Second Year of VIEW Studies

Gisbert Richard

Post Hoc Analysis of Visual Acuity Outcomes in the Second Year of VIEW Studies

Duration 5min, Q&A 3min

FP-FR-17-8 / 

Retina - Medical

2-Year (96-Week) Efficacy and Safety of Intravitreal Aflibercept Injection for Neovascular Age-Related Macular Degeneration in Asian Patients: Subgroup Analysis of VIEW Studies

Tien Ying Wong

2-Year (96-Week) Efficacy and Safety of Intravitreal Aflibercept Injection for Neovascular Age-Related Macular Degeneration in Asian Patients: Subgroup Analysis of VIEW Studies

Duration 5min, Q&A 3min

FP-FR-17-9 / 

Retina - Medical

Correlation of Morphological Parameters in OCT and Vision Outcome in the VIEW2 Trial

Ursula Schmidt-Erfurth

Correlation of Morphological Parameters in OCT and Vision Outcome in the VIEW2 Trial

Duration 5min, Q&A 3min

FP-FR-17-10 / 

Retina - Medical

Correlation of OCT Characteristics and Retinal Sensitivity in Neovascular Age-Related Macular Degeneration (AMD) in the Course of Aflibercept Treatment

Florian Sulzbacher

Correlation of OCT Characteristics and Retinal Sensitivity in Neovascular Age-Related Macular Degeneration (AMD) in the Course of Aflibercept Treatment

Duration 5min, Q&A 3min

FP-FR-17-11 / 

Retina - Medical

Clinical Experience with Intravitreal Aflibercept for Wet Age-Related Macular Degeneration: Initial Benefits May Not Be Maintained with a Regimen of Injections Every 8 Weeks

Arshad Khanani

Clinical Experience with Intravitreal Aflibercept for Wet Age-Related Macular Degeneration: Initial Benefits May Not Be Maintained with a Regimen of Injections Every 8 Weeks

Go back